Federal Register Notice: FDA has determined the regulatory review period for Allergan’s Lumigan (bimatoprost) is 1,967 days for the extension of a patent which claims that human drug product. Lumigan is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are intolerant of other intraocular pressure lowering medications or insufficiently responsive (failed to achieve target IOP determined after multiple measurements over time) to another intraocular pressure lowering medication. To view this notice, click here.
